New PDE Inhibitors

HomeNew PDE Inhibitors
Catalog No. Product Name Information
E1566 Ensifentrine Ensifentrine (RPL-554) is a first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50 values of 0.4 nM and 1479 nM, respectively. Ensifentrine also inhibits lipopolysaccharide-induced tumor necrosis factor alpha release from human monocytes in a concentration-dependent manner. Ensifentrine demonstrates bronchoprotective and anti-inflammatory activities and can be used for chronic obstructive pulmonary disease (COPD) research.
E8284 PM534 PM534 is a potent microtubule-targeting agent (MTA) that binds the colchicine-binding domain (CBD) and inhibits tubulin assembly with IC50 values ranging from 0.8 to 3.2 nM. It also significantly inhibits tumor growth in mouse xenograft models of human non-small cell lung cancer.
E4986 Mirodenafil Mirodenafil (SK3530) is a second-generation, highly selective inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.34 nM, primarily used in the treatment of erectile dysfunction (ED).
E4793 Bucladesine calcium Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation.
≡ All PDE Inhibitors